Primär biliäre Cholangitis – etablierte und neue Therapien

[1]  G. Hirschfield,et al.  Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross‐disease cohort study , 2018, Alimentary pharmacology & therapeutics.

[2]  Deutschen Gesellschaft für Innere Medizin,et al.  [Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27]. , 2017, Zeitschrift fur Gastroenterologie.

[3]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[4]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[5]  A. Burroughs,et al.  University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy , 2022 .

[6]  I. Mackay,et al.  Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. , 2015, Journal of hepatology.

[7]  David C. Jones,et al.  Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’ , 2015, Gut.

[8]  M. Trauner,et al.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.

[9]  A. Burroughs,et al.  Impact of primary biliary cirrhosis on perceived quality of life: The UK‐PBC national study , 2013, Hepatology.

[10]  G. Alexander,et al.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.

[11]  M. Greaves.  Pathogenesis and Treatment of Pruritus , 2010, Current allergy and asthma reports.

[12]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[13]  Masahiro Ito,et al.  Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis , 2007, Hepatology.

[14]  U. Beuers.  Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[15]  A. Papas,et al.  The effectiveness of 10% chlorhexidine varnish treatment on dental caries incidence in adults with dry mouth. , 2000, Gerodontology.

[16]  H. Ackermann,et al.  Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. , 1999, Gastroenterology.

[17]  E. Dickson,et al.  Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. , 1997, Gastroenterology.

[18]  P. Potier,et al.  A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso) , 2017 .

[19]  T. Pusl,et al.  Pathogenesis and Treatment of Pruritus in Cholestasis , 2012, Drugs.

[20]  Y. Chrétien,et al.  Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. , 2012, Journal of hepatology.